Pre-eclampsia diagnosis in 2\textsuperscript{nd} and 3\textsuperscript{rd} trimester of pregnancy

Improved pre-eclampsia diagnosis with sFlt-1 and PIGF • Prognosis of adverse outcome in women with suspected pre-eclampsia • Sensitive and reliable measurement on Thermo Scientific B·R·A·H·M·S KRYPTOR
Pre-eclampsia is a progressive, pregnancy-related disorder with severe complications for mother and child. A timely diagnosis is needed in order to prevent maternal and fetal morbidity or mortality. In the absence of a specific therapy other than delivery the main objective of frequent patient monitoring is to detect deterioration of a patient’s condition and to counteract maternal and fetal risk.

10% of pregnant women show unspecific signs and symptoms of pre-eclampsia. Only one fifth of them are actually developing pre-eclampsia. The “gold standard” for pre-eclampsia diagnosis – assessment of blood pressure and proteinuria – offers only a poor sensitivity and specificity with regards to origin of disease and prediction of maternal and perinatal outcome.
Serum sFlt-1 and PlGF determination adds significant clinical benefit to standard procedures

Determination of the biomarkers sFlt-1 (soluble FMS-like Tyrosine Kinase) and PlGF (Placental Growth Factor) in maternal blood have shown to significantly improve risk stratification among women presenting for pre-eclampsia evaluation.

With the new high sensitivity assays Thermo Scientific™ B·R·A·H·M·S™ sFlt-1 KRYPTOR™ and Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR it is now possible to detect serum levels of both biomarkers reliably throughout pregnancy and thus improve pre-eclampsia management.

... significantly improved by sFlt-1 and PlGF serum measurement

- **Clearly differentiating** between pre-eclampsia and other forms of hypertensive disorders
- **Reliable prediction** of adverse outcome in women with suspected pre-eclampsia
- **Offering potential savings** in hospital costs and resource use

Measuring sFlt-1 and PlGF starting in mid pregnancy in women with suspected pre-eclampsia significantly improves the current evaluation of patients – for a cost-effective patient management and improved care.
Pre-eclampsia diagnosis and prognosis of adverse outcome

The added value of sFlt-1 and PlGF

Improved diagnosis of pre-eclampsia with sFlt-1/PlGF ratio

Recent studies have proved the additional benefit of the sFlt-1/PlGF ratio in diagnosing pre-eclampsia:

- Measurement of sFlt-1 and PlGF levels in maternal serum, starting in mid pregnancy, can confirm pre-eclampsia diagnosis, with the sFlt-1/PlGF ratio having a superior diagnostic ability compared to either of the biomarkers alone.\(^7,8\)

- The addition of sFlt-1/PlGF ratio to Doppler ultrasound measurement improves the sensitivity and specificity in diagnosing pre-eclampsia compared to the Doppler measurement alone.\(^8\)

- In women presenting with hypertension, the sFlt-1/PlGF ratio is able to distinguish between those who will develop pre-eclampsia and those with chronic or gestational hypertension. Women with pre-eclampsia have a significantly higher sFlt-1/PlGF ratio than women with other hypertensive disorders or controls.\(^4,5\)

Therefore, the sFlt-1/PlGF ratio is a valuable tool for confirming or excluding the diagnosis of pre-eclampsia and offers a high clinical value for clinical management, counseling and risk anticipation.

![Figure 1: Improved pre-eclampsia diagnosis with sFlt-1/PlGF ratio](image-url)
Prognosis of adverse outcome with sFlt-1/PIGF ratio

Rana et al. showed that **women with any subsequent adverse outcome** in addition to hypertension had a significantly higher sFlt-1/PIGF ratio than those women without, especially when presenting before week 34 (Figure 2).\(^5\)

**Women who needed to be delivered within the next 2 weeks** after presentation had a significantly higher sFlt-1/PIGF ratio than women who could continue with their pregnancy (Figure 3).\(^5\)

The sFlt-1/PIGF ratio is also a potent predictor for subsequent maternal and fetal adverse outcome in women already diagnosed with pre-eclampsia and can support clinical decisions to avoid severe pregnancy complications.
The role of angiogenic factors
Biomarker levels correlate with severity of disease

sFlt-1 and PI GF are counterparts

Although the cause of pre-eclampsia remains unclear, it is likely that the syndrome may be initiated by an imbalance of placental factors that induce endothelial dysfunction.

**Figure 4** sFlt-1 acts as potent antagonist of PI GF and VEGF by adhering to the receptor-binding domains, thus preventing interaction with endothelial receptors and inducing endothelial dysfunction.

**sFlt-1** is a truncated form of the VEGF receptor Flt-1, circulating freely in the blood. sFlt-1 is produced in the placenta and secreted into the bloodstream, where it binds VEGF and PI GF with high affinity and therefore neutralizes their effects.  

**PI GF** belongs to the Vascular Endothelial Growth Factors (VEGF) family, promoting proliferation and survival of endothelial cells and inducing vascular permeability.
Angiogenic factors during pregnancy

Normal pregnancy
During pregnancy, sFlt-1 levels are stable until weeks 20-24, when they rise steadily until delivery. In contrast, PlGF levels increase progressively in first and second trimester and decrease towards term.10

Pre-eclamptic pregnancy
In women with pre-eclampsia, sFlt-1 levels are significantly increased while concentrations of circulating free PlGF are significantly decreased.10,11

Measuring maternal serum concentrations of sFlt-1 and PlGF can differentiate healthy women from women with pre-eclampsia.7,12 Changes in sFlt-1 and PlGF levels also appear to reflect the severity of the disease: early-onset pre-eclampsia is associated with greater changes in PlGF and sFlt-1 compared to late-onset pre-eclampsia.13
Pre-eclampsia management throughout pregnancy

Improving the outcomes for mother and child

**PIGF and PAPP-A: First trimester screening for timely intervention**

Combined screening for pre-eclampsia in weeks 10-13 can reliably identify women at risk for developing pre-eclampsia.

Combined first trimester screening includes
- serum PIGF and PAPP-A measurement,
- determination of mean arterial pressure (MAP), and
- Uterine Artery Pulsatility Index (UAPI)
resulting in a detection rate of >90% for a fixed false positive rate of 5%.14

An early identification of high-risk women allows for preventive measures and intensified monitoring. Administering low-dose aspirin (<150 mg/day) to high-risk women before 16 weeks of gestation can reduce the incidence of pre-eclampsia by 50%.15

**Facts on pre-eclampsia**

- Multisystem, life-threatening pregnancy-related disorder
- A main reason for maternal and fetal morbidity and mortality16,17
- **Incidence**: 2-8% of pregnancies
- **Definition**: New onset hypertension and proteinuria >20 weeks of gestation in previously normotensive women18
- **HELLP** (Hemolysis, Elevated Liver enzymes, Low Platelets): Severe pre-eclampsia variant occurring in ≈ 20% of symptomatic women; defined by additional affection of liver and coagulation system.20
- **Eclampsia**: Final stage of disease, associated with severe tonic-clonic seizures and coma as well as brain injury, cerebral edema and stroke20

---

**First trimester screening for pre-eclampsia with PIGF and PAPP-A**

Administer low-dose aspirin to high risk patients

<table>
<thead>
<tr>
<th>Week of gestation</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
<th>18</th>
</tr>
</thead>
</table>

sFlt-1/PIGF ratio: Improved diagnosis and prognosis of adverse outcome

First symptoms of pre-eclampsia (hypertension, proteinuria) are observed after 20 weeks of gestation. Diagnosis of pre-eclampsia is difficult, as pre-eclampsia can be confused with other diseases such as pregnancy-induced hypertension.

By adding sFlt-1/PIGF ratio to the current diagnostic standard, the diagnosis of pre-eclampsia in a symptomatic woman can be confirmed or excluded. In women with diagnosed pre-eclampsia, the sFlt-1/PIGF ratio is a potent predictor of subsequent maternal and fetal adverse outcome and can be useful for further patient management.

Figure 6 First clinical symptoms of pre-eclampsia are observed >20 weeks of gestation. The gestational age at onset correlates with the severity of maternal and fetal consequences.
Complete pre-eclampsia portfolio
From safe screening to improved diagnosis
with B·R·A·H·M·S sFlt-1 and PI GF

Thermo Scientific
B·R·A·H·M·S sFlt-1 KRYPTOR

Automated immunofluorescent assay for the quantitative
determination of the concentration of sFlt-1 (soluble FMS-
like Tyrosine Kinase 1, also known as VEGF receptor-1) in
human serum.

• 75 determinations per kit
• 9 min incubation time
• Two-point calibration
• Monoparametric control kit, 3 levels
• Wide measuring range: 22-90000 pg/mL
• Excellent precision

With the lower and upper detection limits of 22 and
90000 pg/mL B·R·A·H·M·S sFlt-1 KRYPTOR provides the
measuring range needed for a reliable detection of clinical
sFlt-1 values throughout pregnancy.
Thermo Scientific
B·R·A·H·M·S PlGF plus KRYPTOR

Automated immunofluorescent assay for the quantitative determination of the concentration of PlGF (Placental Growth Factor) in human serum. The assay is specific for the measurement of human free PlGF-1.

- 75 determinations per kit
- 29 min incubation time
- Single-point calibration
- Monoparametric control kit, 3 levels
- Wide measuring range: 3.6–7000 pg/mL
- Excellent precision

With a detection limit of 3.6 pg/mL and an upper limit of 7000 pg/mL B·R·A·H·M·S PlGF plus KRYPTOR provides the high sensitivity needed for measuring PlGF levels in first trimester as well as a wide measuring range to reliably measure clinical values in second and third trimester.

Exceptionally precise, fast and easy
Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS

15 Years Reliable Results
15 Years Confident Decisions

- All KRYPTOR platforms FMF approved
- In routine use in labs worldwide since 1999
- Excellent precision and data stability
Thermo Scientific B·R·A·H·M·S Biomarkers
Prenatal Screening Markers on KRYPTOR Systems

• B·R·A·H·M·S AFP KRYPTOR  Art. no.: 816.075
• B·R·A·H·M·S Free βhCG KRYPTOR  Art. no.: 809.075
• B·R·A·H·M·S hCG+β KRYPTOR  Art. no.: 841.050
• B·R·A·H·M·S Inhibin A KRYPTOR  (under development)
• B·R·A·H·M·S PAPP-A KRYPTOR  Art. no.: 866.075
• B·R·A·H·M·S PIGF KRYPTOR*  Art. no.: 844.075
• B·R·A·H·M·S PIGF plus KRYPTOR*  Art. no.: 869.075
• B·R·A·H·M·S sFlt-1 KRYPTOR*  Art. no.: 846.075
• B·R·A·H·M·S uE3 KRYPTOR  (under development)
• B·R·A·H·M·S Fast Screen pre I plus Software  Art. no.: 105750

* Available on KRYPTOR compact PLUS

References
6. Schnettler et al. BJOG 2013; 120: 1224-32
9. B·R·A·H·M·S sFlt-1 KRYPTOR Instructions for use, 2013
18. Definition of the American College of Obstetrics and Gynecology

thermocorporate.com/brahms

© 2014 Thermo Fisher Scientific Inc. All rights reserved.
KRYPTOR is a registered trademark of OS bio international, licensed for use by B·R·A·H·M·S, a part of Thermo Fisher Scientific. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. All data regarding specifications, terms and pricing correspond to the existing knowledge at the time of the printing. We are not responsible for any errors, misprints or changes. Reprint, also in parts, solely with prior written consent of B·R·A·H·M·S GmbH.
Thermo Fisher Scientific products are distributed worldwide; not all intended uses and applications mentioned in this printing are registered in every country.

Clinical Diagnostics
Thermo Fisher Scientific
B·R·A·H·M·S GmbH
Neuenhofstr. 25
16761 Henningsdorf
Germany
+49 (0)3302 863 0
+49 (0)3302 863 100 fax
info.brahms@thermofisher.com
www.thermoscientific.com/brahms
www.thermoscientific.com/copeptin
www.thermoscientific.com/proadrenomedullin
www.thermoscientific.com/procalcitonin
www.thermoscientific.com/kryptor

10/304.1